Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangyin Huoxue Shengjin Fang is a Traditional Chinese Medicine (TCM) herbal formula developed for the treatment of Sjogren's syndrome. The formula is designed to address the TCM patterns of yin asthenia generating intrinsic heat toxin and blood stasis due to loss of body fluid. Its therapeutic actions include nourishing yin, promoting blood circulation, and generating body fluids (shengjin) to alleviate symptoms such as dry mouth and eyes. It is typically administered as granules (particles). Clinical studies, such as those conducted by the Shanghai Traditional Chinese Medicine Hospital, evaluate its efficacy in modulating immune responses and inflammatory pathways associated with the disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangyin Huoxue Shengjin Fang.